索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]翁阳阳,许莹,曲晨.速激肽在心血管系统中的作用[J].国际心血管病杂志,2024,02:65-68.
点击复制

速激肽在心血管系统中的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年02期
页码:
65-68
栏目:
综述
出版日期:
2024-03-25

文章信息/Info

Title:
-
作者:
翁阳阳; 许莹; 曲晨
210011 南京医科大学第二附属医院老年医学科（翁阳阳，曲晨）；210008 南京大学医学院附属鼓楼医院重症医学科（许莹）
Author(s):
-
关键词:
速激肽; 炎症反应; 血压; 缺血再灌注; 心肌纤维化
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.02.001
文献标识码:
-
摘要:
速激肽家族主要包括P物质（SP）、神经激肽A（NKA）、神经激肽B（NKB）以及新发现的内啡肽和血激肽等。速激肽通过与神经激肽受体结合在心血管系统中发挥重要作用，参与调节炎症反应、血压、缺血再灌注和心肌纤维化等。该文介绍速激肽及其受体与心血管系统的相关研究进展。
Abstract:
-

参考文献/References

[1] Mishra A, Lal G. Neurokinin receptors and their implications in various autoimmune diseases[J]. Curr Res Immunol, 2021, 2:66-78.
[2] N?ssel DR, Zandawala M, Kawada T, et al. Tachykinins:neuropeptides that are ancient, diverse, widespread and functionally pleiotropic[J]. Front Neurosci, 2019, 13:1262.
[3] Feickert M, Burckhardt BB. Mass spectrometric studies on the peptide integrity of substance P and related human tachykinins in human biofluids[J]. Peptides, 2021, 136:170458.
[4] Garcia-Recio S, Gascón P. Biological and pharmacological aspects of the NK1-receptor[J]. Biomed Res Int, 2015, 2015:495704.
[5] Jambusaria A, Hong Z, Zhang L, et al. Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation[J]. Elife, 2020, 9:e51413.
[6] Al-Ahmad AJ, Pervaiz I, Karamyan VT. Neurolysin substrates bradykinin, neurotensin and substance P enhance brain microvascular permeability in a human in vitro model[J]. J Neuroendocrinol, 2021, 33(2):e12931.
[7] Klede M, Clough G, Lischetzki G, et al. The effect of the nitric oxide synthase inhibitor N-nitro-L-arginine-methyl ester on neuropeptide-induced vasodilation and protein extravasation in human skin[J]. J Vasc Res, 2003, 40(2):105-114.
[8] Levick SP, Brower GL, Janicki JS. Substance P-mediated cardiac mast cell activation: an in vitro study[J]. Neuropeptides, 2019, 74:52-59.
[9] Cutrufo C, Evangelista S, Cirillo R, et al. Protective effect of the tachykinin NK2 receptor antagonist nepadutant in acute rectocolitis induced by diluted acetic acid in guinea-pigs[J]. Neuropeptides, 2000, 34(6):355-359.
[10] Page NM. Neurokinin B and pre-eclampsia: a decade of discovery[J]. Reprod Biol Endocrinol, 2010, 8:4.
[11] Khorasani S, Boroumand N, Lavi Arab F, et al. The immunomodulatory effects of tachykinins and their receptors[J]. J Cell Biochem, 2020, 121(5/6):3031-3041.
[12] Robinson P, Garza A, Moore J, et al. Substance P is required for the pathogenesis of EMCV infection in mice[J]. Int J Clin Exp Med, 2009, 2(1):76-86.
[13] Robinson P, Taffet GE, Engineer N, et al. Substance P receptor antagonism: a potential novel treatment option for viral-myocarditis[J]. Biomed Res Int, 2015, 2015:645153.
[14] Christou H, Khalil RA. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies[J]. Am J Physiol Heart Circ Physiol, 2022, 322(5):H702-H724.
[15] 陇源. 作用于冠状动脉的外（内）源血管活性物质的药理作用研究[D]. 兰州:兰州大学, 2007.
[16] Bubb KJ, Wen HR, Panayiotou CM, et al. Activation of neuronal transient receptor potential vanilloid 1 channel underlies 20-hydroxyeicosatetraenoic acid-induced vasoactivity: role for protein kinase A[J]. Hypertension, 2013, 62(2):426-433.
[17] Kohlmann OJ, Cesaretti ML, Ginoza M, et al. Role of substance P in blood pressure regulation in salt-dependent experimental hypertension[J]. Hypertension, 1997, 29(1 Pt 2):506-509.
[18] Kong ZQ, Fu CY, Chen Q, et al. Cardiovascular responses to intravenous administration of human hemokinin-1 and its truncated form hemokinin-1(4-11) in anesthetized rats[J]. Eur J Pharmacol, 2008, 590(1/3):310-316.
[19] Rupniak NM, Carlson EJ, Shepheard S, et al. Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608[J]. Neuropharmacology, 2003, 45(2):231-241.
[20] Cellier E, Barbot L, Regoli D, et al. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat[J]. Br J Pharmacol, 1997, 122(4):643-654.
[21] Wils J, Duparc C, Cailleux AF, et al. The neuropeptide substance P regulates aldosterone secretion in human adrenals[J]. Nat Commun, 2020, 11(1):2673.
[22] Xu Y, Gu Q, Tang J, et al. Substance P attenuates hypoxia/reoxygenation-induced apoptosis via the Akt signalling pathway and the NK1-receptor in H9C2cells[J]. Heart Lung Circ, 2018, 27(12):1498-1506.
[23] Kim DJ, Moon JY, Kim SM, et al. Substance P improves renal ischemia reperfusion injury through modulating immune response[J]. Front Immunol, 2020, 11:600.
[24] Marco B, Alessandro R, Philippe F, et al. The effect of aging on nerve morphology and substance P expression in mouse and human corneas[J]. Invest Ophthalmol Vis Sci, 2018, 59(13):5329-5335.
[25] Ahn W, Chi G, Kim S, et al. Substance P reduces infarct size and mortality after ischemic stroke, possibly through the M2 polarization of microglia/macrophages and neuroprotection in the ischemic rat brain[J]. Cell Mol Neurobiol, 2023, 43(5):2035-2052.
[26] Souza DG, Mendon?a VA, de A Castro MS, et al. Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat[J]. Br J Pharmacol, 2002, 135(2):303-312.
[27] Umer A, ?ugowska-Umer H, Sch?nborn-Kellenberger O, et al. Tachykinin antagonists reverse ischemia/reperfusion gastrointestinal motility impairment in rats[J]. J Surg Res, 2020, 255:510-516.
[28] Edvinsson L, Ekman R, Hedner P, et al. Congestive heart failure:involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibres[J]. Eur J Clin Invest, 1990, 20(1):85-89.
[29] Peng L, Agogo GO, Guo J, et al. Substance P and fibrotic diseases[J]. Neuropeptides, 2019, 76:101941.
[30] Levick SP, Brower GL, Janicki JS. Substance P-mediated cardiac mast cell activation: an in vitro study[J]. Neuropeptides, 2019, 74:52-59.
[31] Widiapradja A, Kasparian AO, McCaffrey SL, et al. Replacement of lost substance P reduces fibrosis in the diabetic heart by preventing adverse fibroblast and macrophage phenotype changes[J]. Cells, 2021, 10(10):2659.
[32] Meléndez GC, Kavanagh K, Gharraee N, et al. Replacement substance P reduces cardiac fibrosis in monkeys with type 2 diabetes[J]. Biomed Pharmacother, 2023, 160:114365.
[33] Chen FX, Wan Q, Li QL, et al. Substance P prevents doxorubicin induced cardiomyocyte injury by regulating apoptosis and autophagy: in vitro and in vivo evidence[J]. Mol Med Rep, 2022, 25(2):50.
[34] Schooling CM. Genetic validation of neurokinin 3 receptor antagonists for ischemic heart disease prevention in men—a one-sample Mendelian randomization study[J]. EBioMedicine, 2022, 77:103901.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81971317， 81801950）
通信作者：曲晨， E-mail：logairland@163.com
更新日期/Last Update: 2024-03-25